Ordering
  • Test code: 50001
  • Turnaround time:
    5–12 calendar days (7 days on average)
  • Preferred specimen:
    3mL whole blood in a purple-top EDTA tube (K2EDTA or K3EDTA)
  • Alternate specimens:
    Saliva. Assisted saliva and gDNA are not accepted
  • Sample requirements
  • Request a sample kit
Billing
 
Print this page
  1. Test Catalog
  2. Invitae Breast Cancer STAT Panel

Invitae Breast Cancer STAT Panel

Test description

The Invitae Breast Cancer STAT Panel includes up to 9 well-established genes that are associated with a significantly increased risk of developing breast cancer. Accelerated turnaround time (TAT) is needed because physicians and patients often want to make surgical and management decisions as quickly as possible. Individuals who are identified with an inherited pathogenic variant have a higher risk of developing another breast cancer and may choose more aggressive surgery and/or different treatment options based on genetic testing results.

All genes on this panel have published medical management guidelines and are associated with defined hereditary cancer syndromes.

This test is appropriate for breast cancer patients with upcoming cancer-related breast surgeries and/or treatment where genetic testing may inform decisions such as lumpectomy versus mastectomy, single versus double mastectomy, or use of other treatments (such as use of PARP inhibitors or other chemotherapy regimens). Identification of a disease-causing variant may also guide testing and management of at-risk relatives. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.

PTEN: Deletion/duplication analysis covers the promoter region.

Genes tested

Primary panel

BRCA1 BRCA2 CDH1 PALB2 PTEN STK11 TP53

Add-on ATM Gene

ATM

ATM can be added at no additional charge with the same turnaround time.

Add-on CHEK2 Gene

CHEK2

CHEK2 can be added at no additional charge with the same turnaround time.

Order test

Primary panel (7 genes)

BRCA1 BRCA2 CDH1 PALB2 PTEN STK11 TP53

Add-on ATM Gene (1 gene)

ATM can be added at no additional charge with the same turnaround time.

ATM

Panel details and technical assay limitations
Add-on CHEK2 Gene (1 gene)

CHEK2 can be added at no additional charge with the same turnaround time.

CHEK2

Panel details and technical assay limitations

Alternative tests to consider

The BRCA1 and BRCA2 genes can be ordered alone with the Invitae BRCA1 and BRCA2 STAT Panel. Report delivery is guaranteed within 5-12 calendar days (7 days on average) of Invitae receiving the sample.

Clinical information

  • Cowden and Cowden-like syndrome
  • hereditary breast and ovarian cancer syndrome (HBOC)
  • hereditary diffuse gastric cancer syndrome (HDGC)
  • Li-Fraumeni syndrome (LFS)
  • Peutz-Jeghers syndrome (PJS)

The average woman’s lifetime risk of developing breast cancer is 12%. Most cases are sporadic and not inherited; however, approximately 5%-10% of breast cancer is hereditary and due to a pathogenic variant in a disease-causing gene. Pathogenic variants in BRCA1 or BRCA2 account for the majority of hereditary breast and ovarian cancer cases in individuals with a strong family history or an early-onset diagnosis.

The other genes on this panel are also associated with hereditary breast cancer, and their inclusion is expected to increase the clinical sensitivity of this test. Individuals with a pathogenic variant in one of these genes have a significantly increased risk of developing cancer, and many of these cancers may be difficult both to detect and to treat. Identifying those with an underlying hereditary cancer syndrome enables implementation of surgical and/or treatment decisions at the time of diagnosis. These efforts may also result in risk-reduction and early diagnosis of other cancers, increasing the chances of successful treatment and survival.

Individuals with a pathogenic variant in one of these genes have an increased risk of malignancy compared to the average person, but not everyone with such a variant will actually develop cancer. Further, the same variant can present differently, even among family members. Because we cannot predict which cancers may develop, additional medical management strategies focused on cancer prevention and early detection may benefit most patients who are found to have a pathogenic variant.

For gene-associated cancer risks, download our Cancer risk poster.

All of the genes on this panel have autosomal dominant inheritance for hereditary breast cancer. The BRCA2 and PALB2 genes are also associated with autosomal recessive Fanconi anemia. The ATM gene is associated with autosomal recessive ataxia-telangiectasia.

This panel comprises genes for which there are established medical management guidelines. It may be considered for individuals with a personal and/or family history of:

  • breast, ovarian, uterine/endometrial, colon, pancreatic, melanoma, sarcoma, and/or prostate cancer, particularly if early onset (<50 years)
  • male breast cancer
  • breast or ovarian cancer and Ashkenazi Jewish ancestry

There are also some common, general features suggestive of a hereditary cancer syndrome family. These include:

  • cancer diagnosed at an unusually young age
  • different types of cancer that have occurred independently in the same person
  • cancer that has developed in both organs of a set of paired organs (e.g., both kidneys, both breasts)
  • several close blood relatives that have the same type of cancer
  • unusual cases of a specific cancer type (e.g., male breast cancer)

  1. National Comprehensive Cancer Network®, Clinical practice guidelines in oncology. Breast and Ovarian Management Based on Genetic Test Results. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed September 2019.
  2. National Comprehensive Cancer Network®, Clinical practice guidelines in oncology. Management Guidelines for HBOC. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp Accessed September 2015.
  3. National Comprehensive Cancer Network®, Clinical practice guidelines in oncology. Genetic/Familial High Risk Assessment: Breast and Ovarian Version 3.2019. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp Accessed September 2019

For management recommendations, please refer to:

Assay and technical information

Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).

Our sequence analysis covers clinically important regions of each gene, including coding exons and 10 to 20 base pairs of adjacent intronic sequence on either side of the coding exons in the transcript listed below, depending on the specific gene or test. In addition, the analysis covers select non-coding variants. Any variants that fall outside these regions are not analyzed. Any limitations in the analysis of these genes will be listed on the report. Contact client services with any questions.

Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae’s deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements (e.g. inversions, gene conversion events, translocations, etc.) or variants embedded in sequence with complex architecture (e.g. short tandem repeats or segmental duplications), may not be detected. Additionally, it may not be possible to fully resolve certain details about variants, such as mosaicism, phasing, or mapping ambiguity. Unless explicitly guaranteed, sequence changes in the promoter, non-coding exons, and other non-coding regions are not covered by this assay. Please consult the test definition on our website for details regarding regions or types of variants that are covered or excluded for this test. This report reflects the analysis of an extracted genomic DNA sample. In very rare cases, (circulating hematolymphoid neoplasm, bone marrow transplant, recent blood transfusion) the analyzed DNA may not represent the patient's constitutional genome.

Gene Transcript reference Sequencing analysis Deletion/Duplication analysis
ATM* NM_000051.3
BRCA1* NM_007294.3
BRCA2* NM_000059.3
CDH1 NM_004360.3
CHEK2 NM_007194.3
PALB2 NM_024675.3
PTEN* NM_000314.4
STK11 NM_000455.4
TP53* NM_000546.5

ATM: Sequencing analysis for exons 6, 24, 43 includes only cds +/- 10 bp.
BRCA1: Sequence analysis includes +/- 20 base pairs of adjacent intronic sequence.
BRCA2: Sequence analysis includes +/- 20 base pairs of adjacent intronic sequence.
PTEN: Deletion/duplication analysis covers the promoter region. Sequencing analysis for exons 8 includes only cds +/- 10 bp.
TP53: Deletion/duplication analysis covers the promoter region.

Clinical resources
Genes and associated cancers chart Hereditary cancer requisition form and gene list Hereditary cancer risks and references chart Invitae brochure
Patient resources
Patient guide: Genetic testing for hereditary cancer Patient guide: Genetic testing simplified Patient guide: Hereditary breast cancer Patient guide: Hereditary colorectal cancer
Test information
Forms page Specimen requirements page

References

  1. National Comprehensive Cancer Network®, Clinical practice guidelines in oncology. Breast and Ovarian Management Based on Genetic Test Results. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed September 2019.
  2. National Comprehensive Cancer Network®, Clinical practice guidelines in oncology. Genetic/Familial High Risk Assessment: Breast and Ovarian Version 3.2019. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp Accessed September 2019
  3. National Comprehensive Cancer Network®, Clinical practice guidelines in oncology. Management Guidelines for HBOC. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp Accessed September 2015.

Headquarters | 458 Brannan Street, San Francisco, CA 94107

Laboratory & Shipping | 475 Brannan Street, Suite 230, San Francisco, CA 94107 | www.invitae.com

In the US | clientservices@invitae.com | p: 800-436-3037 | f: 415-276-4164

Outside the US | globalsupport@invitae.com or visit www.invitae.com/contact

©2015 Invitae Corp. All rights reserved.